TetraLogic Pharmaceuticals

^{Priced, Nasdaq: TLOG}

Developing small molecule therapeutics for the treatment of cancer.

Industry: Health Care

First Day Return: 0.0%

TLOG

Developing small molecule therapeutics for the treatment of cancer.

IPO News for TetraLogic Pharmaceuticals

Cancer biotech Loxo Oncology sets terms for $57 million IPO 07/21/14
US IPO Recap: 221 IPOs for the year, most in a decade 12/16/13
TetraLogic prices relaunched IPO at $7 12/12/13

IPO Data
IPO Date	12/11/2013
Offer Price	IPO Intelligence Only
Price Range	IPO Intelligence Only
Offer Shares (mm)	IPO Intelligence Only
Deal Size ($mm)	$50
Lock-Up Date	IPO Intelligence Only
Street Research	IPO Intelligence Only

Underwriters
IPO Intelligence Only

Company Data
Website www.tetralogicpharma.com
Headquarters	Malvern, PA, United States
Founded	2001
Employees at IPO	20

IPO News for TetraLogic Pharmaceuticals

Cancer biotech Loxo Oncology sets terms for $57 million IPO 07/21/14
US IPO Recap: 221 IPOs for the year, most in a decade 12/16/13
TetraLogic prices relaunched IPO at $7 12/12/13

TetraLogic Pharmaceuticals (TLOG) Performance